Conference abstractPublished 12 Jul 2019
A Fund Managerand#8217;s Investment Outlook on the Biotechnology and Pharmaceutical Sectors
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Biotechnology and pharmaceutical stocks have significantly outperformed broader equity benchmarks over the past 10 years, but these companies remain uniquely difficult to value and risk manage, even for professional investors. Fund Manager Tariq Dennison presents a financial outlook of stocks in the biotechnology and pharmaceutical sectors, starting with a top-down look at how broad and industry focused funds and ETFs choose to invest in these sectors, using examples from actual funds. Next, a few examples of financial models of select companies are highlighted to show some of the challenges and opportunities in valuing shares of companies focused on different stages of drug development. Research and early development stage companies are more often valued and risk managed using a “real options” model, while later stage companies with mature cash flows may be valued with classic “discounted cash flow” models. These top-down and bottom up views are then combined to pave an outlook for investing in funds and shares in the bio & pharma space, and what factors might change fund managers’ views. Valuation is a key emphasis of this presentation and main difference between a practitioner and investor in technologies, since it is easy to lose money investing in even the best technologies if the price paid is too high. Recent Publications: 1. Dennison T (2018) Invest Outside the Box: Understanding Different Asset Classes and Strategies, Pallgrave McMillan. 2. Dennison T (2018) 10 First Stocks to Buy a 10-year Old to Start Investing Early. Seeking Alpha. 3. Dennison T (2017) The World’s Most Valuable Brands Trading at Below-Market Valuations. Seeking Alpha. 4. Dennison T (2018) The 7 Cs of How Tesla Might Crash (But Not Burn) Seeking Alpha. 5. Dennison T (2017) Understanding How Leveraging and Rebalancing Work. Asia Asset Management.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutica Analytica Acta
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Tariq Dennison”
